Trinity Biotech plc
TRIB
$0.34
$0.000.00%
NASDAQ
| 12/31/2025 | 06/30/2025 | 12/31/2024 | 09/30/2024 | 09/30/2022 | |
|---|---|---|---|---|---|
| Revenue | -30.18% | -31.64% | 18.09% | 3.24% | -28.63% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -30.18% | -31.64% | 18.09% | 3.24% | -28.63% |
| Cost of Revenue | -34.66% | -38.49% | 23.91% | -5.32% | 17.33% |
| Gross Profit | -20.07% | -19.55% | 6.79% | 24.02% | -96.30% |
| SG&A Expenses | -30.90% | 8.64% | 20.72% | -15.15% | -15.74% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -200.60% | -- | -- | -- | 97.67% |
| Total Operating Expenses | -46.20% | -20.99% | 33.83% | -9.42% | 6.48% |
| Operating Income | 83.69% | -80.14% | -94.46% | 50.69% | -430.49% |
| Income Before Tax | -11.72% | 17.64% | -187.18% | 26.22% | -723.74% |
| Income Tax Expenses | -129.74% | 324.43% | 19,600.00% | -115.77% | -99.20% |
| Earnings from Continuing Operations | -6.67% | 11.69% | -197.98% | 29.18% | -839.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 3,696.55% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.07% | 11.69% | -208.23% | 29.19% | -777.14% |
| EBIT | 83.69% | -80.14% | -94.46% | 50.69% | -430.49% |
| EBITDA | 89.67% | -54.95% | -149.36% | 62.05% | -300.43% |
| EPS Basic | -322.05% | 55.15% | 69.16% | 47.74% | -471.36% |
| Normalized Basic EPS | -- | 42.18% | -- | -- | -- |
| EPS Diluted | -130.40% | 43.97% | 39.80% | 47.74% | -493.33% |
| Normalized Diluted EPS | -- | 42.18% | -- | -- | -- |
| Average Basic Shares Outstanding | 4.19% | 96.86% | 134.61% | 35.50% | 82.32% |
| Average Diluted Shares Outstanding | 4.19% | 96.87% | 134.62% | 35.52% | 74.55% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |